Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Research Note

SARS-CoV-2 N gene dropout and N gene Ct value shift as indicator for the presence of B.1.1.7 lineage in a commercial multiplex PCR assay

Paul Wollschlager 1, 1, Daniel Todt 2, 3, 1, Nadja Gerlitz 1, Stephanie Pfänder 2, Thomas Bollinger 4, Andreas Sing 5, Alexandra Dangel 5, Nickolaus Ackermann 5, Klaus Korn 6, Armin Ensser 6, Eike Steinmann 2, Michael Buhl 1, 1, Joerg Steinmann 1, *, 5

1) Institute of Clinical Hygiene, Medical Microbiology and Infectiology, Paracelsus Medical University, Nuremberg, Germany
2) Department of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany
3) European Virus Bioinformatics Center (EVBC), Jena, Germany
4) Microbiology, Laboratory Medicine, Klinikum Bayreuth GmbH, Bayreuth, Germany
5) Bavarian Health and Food Safety Authority (LGL), Oberschleissheim, Germany
6) Institute of Clinical and Molecular Virology, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany

ARTICLE INFO

Article history:
Received 23 March 2021
Received in revised form
12 May 2021
Accepted 13 May 2021
Available online 24 May 2021
Editor: F. Allerberger

Keywords:
B.1.1.7
Diagnostic quantitative RT-PCR
Mutation
SARS-CoV-2
VOC

ABSTRACT

Objectives: Detection and surveillance of SARS-CoV-2 is of eminent importance, particularly due to the rapid emergence of variants of concern (VOCs). In this study we evaluated if a commercially available quantitative real-time PCR (qRT-PCR) assay can identify SARS-CoV-2 B.1.1.7 lineage samples by a specific N gene coding sequence of SARS-CoV-2 with and without the D3L mutation (specific for B.1.1.7) was cloned into pCR™II-TOPO™ vectors to validate polymorphism-dependent N gene dropout or Ct value shift compared with the S or RdRp gene.

Methods: VOC B.1.1.7 and non-B.1.1.7 SARS-CoV-2-positive patient samples were identified via whole-genome sequencing and variant-specific PCR. Confirmed B.1.1.7 (n = 48) and non-B.1.1.7 samples (n = 58) were analysed using the Allplex™ SARS-CoV-2/FluA/FluB/RSV™ PCR assay for presence of SARS-CoV-2 S, RdRp and N genes. The N gene coding sequence of SARS-CoV-2 with and without the D3L mutation (specific for B.1.1.7) was detected in reverse genetic experiments, using isolated plasmids containing N gene coding sequences corresponding to D3 or 3L variants.

Results: All studied B.1.1.7-positive patient samples showed significantly higher Ct values in qRT-PCR (ΔCt > 10, N gene dropout on Ct values > 29) of N gene than the corresponding values of S (p < 0.0001) and RdRp (p < 0.0001) genes. The assay reliably discriminated B.1.1.7 and non-B.1.1.7 positive samples (under the curve = 1) in a receiver operating characteristic curve analysis. Identical Ct value shifts (> 10) were detected in reverse genetic experiments, using isolated plasmids containing N gene coding sequences corresponding to D3 or 3L variants.

Discussion: An N gene dropout or Ct value shift is shown for B.1.1.7-positive samples in the Allplex™ SARS-CoV-2/FluA/FluB/RSV™ PCR assay. This approach can be used as a rapid tool for B.1.1.7 detection in single assay high throughput diagnostics.

P. Wollschlager, Clin Microbiol Infect 2021;27:1353.e1–1353.e5 © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
(UK) [3] are among the most prevalent ones. The B.1.1.7 variant has been associated with increased mortality [4] and risk of transmission [5] and is rapidly expanding its geographic range worldwide. Therefore, early identification of this variant in patients may help reduce further spread of infection. Each lineage is characterized by a combination of single mutations across the SARS-CoV-2 genome, and while some are shared between aforementioned lineages, others are specific for one individual lineage. For example, amino acid exchange N501Y in the SARS-CoV-2 spike protein (S) is present in all three mentioned lineages, whereas the additional deletion H69/V70 in the same protein is present in B.1.1.7, but not in the other two VOCs B.1.351 and P.1 [3]. B.1.1.7 also has a specific single nucleotide polymorphism in the N gene (D3L) which can be targeted by PCR assays.

Multiplex PCR is considered as the reference standard for SARS-CoV-2 detection, and dual or triple target approaches are recommended [6,7]. However, identification of viral variants is not intended with regular PCR kits. The presence of SARS-CoV-2 variants in a patient sample can potentially change the performance of a SARS-CoV-2 assay. Some studies have reported dropouts of various genes targeted by SARS-CoV-2 multiplex PCR approaches affecting the S gene [8,9], N gene [10,11] or E gene [12], which may allow presumptive identification of specific lineages. While spread of VOCs is an imminent danger worldwide, rapid detection of VOCs is limited by the turnaround time and costs, or availability of methods such as next-generation sequencing or variant-specific PCR, respectively. Here, we report an approach which allows for presumptive identification of the B.1.1.7 lineage by calculating a score from the Ct values of the target genes included in the Allplex™ SARS-CoV-2/FluA/FluB/RSV assay (Seegene, South Korea), thus greatly speeding up the time to result of laboratory diagnosis of this lineage.

Materials and methods

Nucleic acid extraction from patient swabs was performed on Seegene Nimbus IVD using the STARMag 96 X 4 Viral DNA/RNA 200 C Kit (Seegene). Amplification and detection of SARS-CoV-2 via qRT-PCR was performed with Allplex™ SARS-CoV-2/FluA/FluB/RSV or Allplex™ 2019-nCoV assays, respectively (Seegene).

Isolated RNA (one confirmed UK variant B.1.1.7 and one non-B.1.1.7) was reversed transcribed using SuperScript™ IV First-Strand Synthesis System (ThermoFisher Scientific) with specific primer AS-CoV2_N_3 ’ (5’-TATTGCCGTAGTTAGTACGCAG-3’). Subsequent amplification of the entire N gene region was achieved using Platinum™ Taq DNA Polymerase High Fidelity (ThermoFisher Scientific) and forward primer S-CoV2_N_D3_5’ (5’-CAACACTA-AAATGTCGTGATAATTGACCCTACTAATCC-3’) or S-CoV2_N_D3_5’ (5’-CAACTAAATTGTCCTTAAATGAGCTCCCCAATA-3’) combined with reverse primer AS-CoV2_N_3’. PCR products were cloned into the pCRII-TOPO™ vector backbone using TOPO™ TA Cloning™ Kit (ThermoFisher Scientific) and propagated by transformation of TOP10 competent Escherichia coli. The presence of D3 or 3L variant was confirmed via Sanger sequencing (Fig. S1).

For validation of D3L polymorphism specific Ct value shift in the N gene, each plasmid was diluted to an initial copy number of 1.25 × 10⁸ and, subsequently diluted to 1:10, 1:100 and 1:1,000 dilutions. To imitate extraction and test conditions, 0.5 µl of each dilution was then mixed with 500 µl of viral transport medium containing a negative tested nasopharyngeal swab and treated as described above.

Patient samples were identified by variant-specific PCR (Novaplex™ SARS-CoV-2 Variants 1 assay (Seegene)) or by whole-genome sequencing using Illumina MiSeq and Novaseq 6000 (LGL, Oberschleißheim, Germany; Synlab MVZ, Weiden, Germany).

The study was approved by the institutional review board of the Paracelsus Medical University, Nuremberg, Germany (reference number IRB 2021-008).

Statistical analysis was performed using GraphPad Prism version 9.1.0 for Windows (GraphPad Software, San Diego, CA, USA).

Results

A qRT-PCR assay, based on a triple target approach is routinely used for SARS-CoV-2 detection (S gene, RdRp gene and N gene). Using this method, we noticed significant N gene-specific changes in Ct values for the N target compared with results for S gene and RdRp gene (p < 0.0001), initially occurring in early 2021 (Fig. 1A). A total of 48 consecutive samples, all showing N gene dropouts (n = 6) or N gene cycle threshold (Ct) value shifts (n = 42) (∆Ct N/RdRp or ∆Ct N/S > 6) were collected for further analysis aiming at lineage-specific assignment of the respective SARS-CoV-2 strains.

In addition, a selection of 58 samples with unsuspicous ∆Ct N/RdRp or ∆Ct N/S(≤6) were included as controls. To this end, either whole-genome sequencing (n = 23) or variant-specific PCR (n = 25) were performed. These analyses revealed that all of the samples which had previously yielded N gene-specific Ct value shifts or dropouts (∆Ct N/RdRp or ∆Ct N/S score > 6) belonged to the B.1.1.7 lineage, whereas the remaining 58 SARS-CoV-2 positive samples with ∆Ct N/RdRp or ∆Ct N/S ≤ 6 were all classified as non-B.1.1.7 variants (B.1.1.317 (n = 2), B.1.351 (n = 1), N501Y-, E484K+ (n = 1), N501Y-, E484K- (n = 1) and N501Y-, Del. H69/V70- (n = 53), reflecting the local epidemiology in early 2021 (Tables S1 and S2).

The observed N gene Ct value shift or N gene dropout was detectable regardless of whether samples were strongly or weakly positive for SARS-CoV-2, as evident from the broad range of Ct values for N.B.1.1.7 and non-B.1.1.7 (Fig. 1A). For S or RdRp targets we did not observe any shifts in Ct values (Fig. S2). Delta Ct values of 4.11 and 4.38 were identified in a receiver operating characteristic (ROC) curve analysis to discriminate B.1.1.7 and non-B.1.1.7 variants with 100% sensitivity and specificity using ∆Ct N/RdRp (95% CI sensitivity 91.62–100% and 95% CI specificity 93.79–100%), and ∆Ct N/S (95% CI sensitivity 91.62–100% and 95% CI specificity 93.79–100%), respectively (Fig. 1B). Similar shifts in ∆Ct for S/RdRp were not observed (Fig. 1B). In addition, comparative linear regression analysis of ∆Ct N/S or ∆Ct N/RdRp values revealed no significant differences in slopes (∆Ct N/S p = 0.474, ∆Ct N/RdRp p = 0.446), while elevations of lines (y- intercepts) differed significantly (∆Ct N/S p ≤ 0.0001, ∆Ct N/RdRp p ≤ 0.0001) (Fig. 1C). Concluding, ∆Ct value shifts observed for both N/RdRp and N/S allow for meaningful classification of B.1.1.7 versus non-B.1.1.7 (no overlap/ outliers).

A subset of the samples with N gene Ct value shift or N gene dropout were tested by two other commercially available SARS-CoV-2 PCR assays. Neither the Allplex™ 2019-nCoV (Seegene) nor the VIASURE SARS-CoV-2 (CerTest, for BD MAX™ System) showed N gene Ct value shift or N gene dropout.

To elucidate the underlying molecular mechanism resulting in the observed N gene dropout or Ct value shift, we cloned the N gene coding sequence with and without D3L mutation into pCRII-TOPO™ vectors which were then used for PCR analysis.

Again, we found a shift in Ct values ∆Ct N/Sfl/Nil 7.1–10.1 for the 3L but not for D3 variant N gene using the Allplex™ SARS-CoV-2/FluA/FluB/RSV assay, whereas Allplex™ 2019-nCoV did not show any shift in Ct (∆Ct N/Sfl/Nil 0.1–1.07) values for both variants (Fig. 2A, Table S3). Here, comparative linear regression analysis
Fig. 1. The Allplex™ SARS-CoV-2/FluA/FluB/RSV assay reliably discriminates SARS-CoV-2 B.1.1.7 from non-B.1.1.7 positive patient specimens. (A) Violin plots with median (solid black lines), quartiles (dashed black lines) and individual data points (open circles) of determined cycle threshold (Ct) values for B.1.1.7 and non-B.1.1.7 positive patient specimens in qRT-PCR for three genes, S, RdRp and N. ****p ≤ 0.0001 in one-way ANOVA followed by Tukey’s multiple comparison test, ns – not significant. (B) Receiver operating characteristic (ROC) curves discriminating absolute differences in Ct values of B.1.1.7 and non-B.1.1.7 positive patient specimens between N gene and S gene (left panel), N gene and RdRp gene (middle panel) and S gene and RdRp gene (right panel). Lower respective panels display differences in Ct values; dashed lines indicate Ct with 100% sensitivity and specificity (95% CI sensitivity 91.62–100% and CI specificity 93.79–100%) as determined in ROC curves. (C) Pearson correlation (r) and comparative linear regression of Ct values of N gene and S gene (left panel) and N gene and RdRp gene of B.1.1.7 (blue line and 99% prediction band) and non-B.1.1.7 (grey line and 99% prediction band) positive patient specimens, respectively. No significant difference in slope is determined (CtS/CtN = 0.474, CtS/CtRdRp p = 0.446), y-intercepts (elevations) differ significantly (****p ≤ 0.0001).
identified no significant discrepancy in slopes of the curves (Ct \(N_D3/N_{3L}\) p 0.212), while intercepts differed significantly (Ct \(N_D3\) p 0.0001) in the two assays (Fig. 2B). This confirmed that the D3L mutation can be identified by the Allplex™ SARS-CoV-2/FluA/FluB/RSV assay, but not by the Allplex™ 2019-nCoV test (Fig. 2).

**Discussion**

*N* gene dropout or Ct value shift as indicator for B.1.1.7 positive samples

We were able to demonstrate that all confirmed B.1.1.7 samples have an *N* gene dropout or Ct value shift compared with the *S* or RdRp gene for SARS-CoV-2 by the Allplex™ SARS-CoV-2/FluA/FluB/RSV assay. These *N* gene dropouts or Ct value shifts were caused by a D3L mutation in the *N* gene of SARS-CoV-2 which was confirmed by reverse genetics. In contrast, strains of other lineages were not affected by *N* gene dropouts or Ct value shifts. Mutations in the *N* gene are known to occur less often than in other regions of the SARS-CoV-2 genome [13–17]. Nevertheless, mutations of *N* gene D3 also occur in other lineages, where D3 is replaced by an amino acid other than leucine. For example, D3Y is present in the variant of interest B.1.525, which currently represents less than 1% of the SARS-CoV-2 population [18,19]. While *S* gene dropouts have been reported for the TaqPath COVID-19 assay (ThermoFisher, USA), to the best of our knowledge, this is the first report of *N* gene dropout or Ct value shift with diagnostic relevance as a marker for VOC differentiation (Allplex™ SARS-CoV-2/FluA/FluB/RSV assay). However, the *N* gene dropout has a higher specificity for the B.1.1.7 lineage, as it does not occur in other VOCs and most other lineages.

**Allplex™ SARS-CoV-2/FluA/FluB/RSV assay can be used as fast detection tool for presumptive identification of the B.1.1.7 lineage**

Detection of SARS-CoV-2 variants has become an additional task for many laboratories, which can be a time critical challenge. As whole-genome sequencing is the reference standard to detect, track and monitor virus variants (surveillance), this method is neither accessible everywhere nor easy to perform. Especially in clinical
contexts, fast identification of VOC lineages is crucial for patient management in both inpatient and outpatient settings (infection control and prevention measures including contact tracing). While by now most laboratories have implemented workflows to deliver SARS-CoV-2 qRT-PCR results in a timely manner, variant-specific discrimination of positive samples requires additional resources and thus delays reporting of VOCs. This counteracts public health strategies aiming at slowing down the fast spread of VOCs which due to their increased transmissibility, tends to occur at higher rates.

This study has some limitations. Although N gene shift or dropout was detectable in all 48 B.1.1.7-positive specimens, sample size was rather small. Second, the assay is probably not 100% specific for B.1.1.7 because mutations of the N gene can also occur in other variants like B.1.525. In addition to the detection of four viral respiratory pathogens (SARS-CoV-2, Influenza A and B plus RSV), the Allplex™ SARS-CoV-2/FluA/FluB/RSV assay allows for presumptive assignment of SARS-CoV-2 positive samples to the B.1.1.7 lineage in a one-step approach by using the proposed ΔCt N/RdRp or N/S score. However, confirmation of this presumptive result is warranted as the Allplex™ SARS-CoV-2/FluA/FluB/RSV assay is not intended for detection of VOCs by the manufacturer.

In conclusion, this approach can be used as a rapid tool for B.1.1.7 indication and surveillance in high throughput diagnostics.

Transparency declaration

J.S. received lecture honoraria from Pfizer and Gilead, unrelated to the current study. All other authors declare no conflict of interest. Part of the work was funded by the Bavarian State Ministry of Health and Care, Germany (Verbundprojekt “BAY-VOC”). The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board, Paracelsus Medical University, Nuremberg, Germany (reference number IRB-2021-008; 22 March 2021).

Author contributions

Designed experiments: W.P., G.N., T.D., P.S., S.E., S.J. Performed experiments: W.P., G.N., T.D. Provided important samples and data: W.P., G.N., T.D., P.S., B.T., S.A., D.A., A.N., K.K., E.A., S.E., B.M., S.J. Wrote the manuscript: W.P., G.N., T.D., B.M., S.J.

Acknowledgement

We would like to thank all members of the Institute of Clinical Hygiene, Medical Microbiology and Infectiology, Paracelsus Medical University for support and fruitful discussion.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.cmi.2021.05.025.